



**STATE OF NEVADA
OFFICE OF THE ATTORNEY GENERAL
BUREAU OF CONSUMER PROTECTION**

2026 ANNUAL REPORT FOR
CONTINGENT FEE CONTRACTS FOR LEGAL SERVICES
FOR THE 2025 CALENDAR YEAR

TABLE OF CONTENTS

	<u>Page</u>
I. Introduction.....	2
II. Contingent Fee Contracts	2
A. Opioid Investigation and Litigation Contingent Fee Contract	2
1. Name and Address of Retained Law Firm	2
2. Nature and Present Status of Matter that is the Subject of the Contract.....	2
3. Name of Each Party to the Matter	3
4. Amount of Recovery Obtained in the Matter	4
5. Amount of Costs and Expenses Paid in the Prosecution of the Matter for which No Recovery was Obtained	4
6. Amount of Any Fee Paid pursuant to the Contract.....	4
B. Social Media Platforms Investigation and Litigation Contingent Fee Contract.....	5
1. Name and Address of Retained Law Firm	5
2. Nature and Present Status of Matter that is the Subject of the Contract.....	5
3. Name of Each Party to the Matter	6
4. Amount of Recovery Obtained in the Matter	6
5. Amount of Costs and Expenses Paid in the Prosecution of the Matter for which No Recovery was Obtained	7
6. Amount of Any Fee Paid pursuant to the Contract.....	7
III. Determinations and Attachments.....	8
IV. Contact.....	8

I. Introduction

Pursuant to Nevada Revised Statutes (“NRS”) 228.1118, the Office of the Attorney General hereby submits this 2026 annual report to the Director of the Legislative Counsel Bureau, for transmittal to the Majority Leader of the Senate and the Speaker of the Assembly, describing the use of the contingent fee contracts entered into by the Office of the Nevada Attorney General for the proceeding calendar year. This 2026 Annual Report covers the 2025 calendar year reporting period (“calendar year reporting period”).

II. Contingent Fee Contracts

A. Opioid Investigation and Litigation Contingent Fee Contract

Pursuant to NRS 228.111 *et seq.*, a contract relating to retained legal services for the Opioid Investigation and Litigation (“Opioid Contract”) was approved by the Interim Finance Committee on January 30, 2019, solicited through the Nevada State Purchasing Division, and entered into by the Office of the Nevada Attorney General Bureau of Consumer Protection on May 2, 2019. The Opioid Contract and related information is posted on the website of the Office of the Nevada Attorney General, and can be found here:

https://ag.nv.gov/Hot_Topics/Opioid_Epidemic/

1. Name and Address of Retained Law Firm

Eglet Law Group, LLP
400 South 7th Street, 4th Floor
Las Vegas Nevada 89101

2. Nature and Present Status of Matter that is the Subject of the Contract

The Opioid Investigation and Litigation (“Opioid Investigation and Litigation”) seeks to hold companies and individuals accountable for their contributions to the opioid epidemic in the State of Nevada.

Case No. A-19-796755-B:

The State commenced litigation by Amended Complaint on June 27, 2019, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-19-796755-B. The State filed a Second Amended Complaint on March 9, 2021. This matter resulted in numerous settlements and is stayed by Federal Bankruptcy courts for certain defendants.

Case No. A-24-885923-C:

The State commenced litigation by Complaint on January 26, 2024, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-24-885923-C. This matter was removed to the United States District Court for the District of Nevada and was remanded back to State Court on March 30, 2025. An Amended Complaint was filed on November 24, 2025. This matter is in motion practice.

3. Name of Each Party to the Matter

Case No. A-19-796755-B:

Plaintiff(s): STATE OF NEVADA

Defendant(s): MCKESSON CORPORATION; CARDINAL HEALTH INC.; CARDINAL HEALTH 105, INC.; CARDINAL HEALTH 108, LLC; CARDINAL HEALTH 110, LLC; CARDINAL HEALTH 200, LLC; CARDINAL HEALTH 414, LLC; CARDINAL HEALTH PHARMACY SERVICES, LLC; AMERISOURCEBERGEN DRUG CORPORATION; WALGREENS BOOTS ALLIANCE, INC.; WALGREEN CO.; WALGREEN EASTERN CO., INC.; WALMART INC.; CVS PHARMACY, INC.; TEVA PHARMACEUTICALS USA.; TEVA PHARMACEUTICAL INDUSTRIES, LTD.; CEPHALON, INC.; ACTAVIS PHARMA, INC.; ALLERGAN FINANCE, LLC (fka ACTAVIS, INC. fka WATSON PHARMACEUTICALS, INC.); WATSON LABORATORIES, INC.; ACTAVIS, LLC; PURDUE PHARMA L.P.; PURDUE PHARMA, INC.; PURDUE HOLDINGS, L.P.; THE PURDUE FREDERICK COMPANY, INC.; P.F. LABORATORIES, INC.; RICHARD S. SACKLER; JONATHAN D. SACKLER, MORTIMER D.A. SACKLER; KATHE A. SACKLER; ILENE SACKLER LEFCOURT; DAVID A. SACKLER; BEVERLY SACKLER; THERESA SACKLER; PLP ASSOCIATES HOLDINGS L.P.; ROSEBAY MEDICAL COMPANY L.P.; BEACON COMPANY; ENDO HEALTH SOLUTIONS INC.; ENDO PHARMACEUTICALS, INC.; PAR PHARMACEUTICAL, INC.; MALLINCKRODT PLC; MALLINCKRODT LLC; SPECGX LLC; JOHNSON & JOHNSON; JANSSEN PHARMACEUTICALS, INC.; NORAMCO, INC.; CVS TN DISTRIBUTION LLC; LONGS DRUG STORE CALIFORNIA LLC; AMERICAN DRUG STORES; STEVEN A. HOLPER; STEVEN A. HOLPER MD PROFESSIONAL CORPORATION; HOLPER OUT-PATIENTS MEDICAL CENTER, LTD.; ROBERT GENE RAND; RAND FAMILY CARE LLC; DEVENDRA I. PATEL; PATEL NORTH EASTERN NEVADA CARDIOLOGY PC; HORACE PAUL GUERRA IV; ALEJANDRO JIMINEZ INCERA; ROBERT D. HARVEY; INCERA-IUVENTUS MEDICAL GROUP PC; INCERA LLC; DOE ENTITIES 1-10.

Case No. A-24-885923-C:

Plaintiff(s): STATE OF NEVADA

Defendant(s): OPTUM, INC.; OPTUMRX, INC.; OPTUMINSIGHT LIFE SCIENCES, INC.; OPTUMINSIGHT, INC.; UNITEDHEALTH GROUP, INC.; THE LEWIN GROUP, INC.; EVERNORTH HEALTH, INC.; EXPRESS SCRIPTS, INC.; EXPRESS SCRIPTS ADMINISTRATORS, LLC; ESI MAIL PHARMACY SERVICE, INC.; EXPRESS SCRIPTS PHARMACY, INC.; EXPRESS SCRIPTS SPECIALTY DISTRIBUTION SERVICES, INC.; MEDCO HEALTH SOLUTIONS, INC.; ELEVANCE HEALTH, INC.; CARELONRX, INC.; CARELON INSIGHTS, INC.; DOE ENTITIES 1-10.

4. Amount of Recovery Obtained in the Matter

Total recoveries for the Opioid Investigation and Litigation are made pursuant to the Opioid Contract and One Nevada Agreement on Allocation of Opioid Recoveries (“One Nevada Agreement”), which can be found here: https://ag.nv.gov/Hot_Topics/Opioid_Epidemic/

The One Nevada Agreement is an agreement entered into by the State of Nevada, every Nevada county, and each Nevada city and district that has active opioid-related litigation, for the purpose of fairly and equitably allocating recoveries in their respective opioid litigations.

Case No. A-19-796755-B:

The amount of recoveries obtained, including the amount of recoveries for the calendar year reporting period, are depicted in the attached Exhibit A – Summary Totals and Exhibit B – State Summary.

Exhibit A – Summary Totals illustrates the total amount of recoveries actually received and anticipated to be received through settlements and bankruptcies.

Exhibit B – State Summary illustrates the amount of recoveries allocated to the Fund for a Resilient Nevada established pursuant to NRS 433.732.

Case No. A-24-885923-C:

There were no recoveries obtained during the calendar year reporting period.

5. Amount of Costs and Expenses Paid in the Prosecution of the Matter for which No Recovery was Obtained

Case No. A-19-796755-B:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the calendar year reporting period.

Case No. A-24-885923-C:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the calendar year reporting period.

6. Amount of Any Fee Paid pursuant to the Contract

A contingency fee has been negotiated that is dependent on the amount of recovery for the Opioid Investigation and Litigation.

Case No. A-19-796755-B:

The amount of attorney fees paid, including the amount of attorney fees paid during the calendar year reporting period, by the State of Nevada for the recoveries that have been obtained are presented in the attached Exhibit B – State Summary.

Case No. A-24-885923-C:

There were no amount of attorney fees paid during the calendar year reporting period.

B. Social Media Platforms Investigation and Litigation Contingent Fee Contract

Pursuant to NRS 228.111 *et seq.*, a contract relating to retained legal services for the Social Media Platforms Investigation and Litigation (“SMP Contract”) was approved by the Interim Finance Committee on October 11, 2023, solicited through the Nevada State Purchasing Division, and entered into by the Office of the Nevada Attorney General Bureau of Consumer Protection on December 4, 2023. The SMP Contract and related information is posted on the website of the Office of the Nevada Attorney General, and can be found here:

https://ag.nv.gov/Hot_Topics/Social_Media_Platforms_Investigation_and_Litigation/

1. Name and Address of Retained Law Firm

Kemp Jones, LLP

3800 Howard Hughes Pkwy

Seventeenth Floor

Las Vegas, NV 89169

Nachawati Law Group

5489 Blair Road

Dallas, TX 75231

WHLaw

1 Riverfront Place, Suite 745

North Little Rock, AR 72114

2. Nature and Present Status of Matter that is the Subject of the Contract

The Social Media Platforms Investigation and Litigation (“SMP Investigation and Litigation”) seeks to hold companies and individuals accountable for their contributions to the harms, risks, and impacts to the State of Nevada and its residents, particularly its youth, from social media platforms. The State commenced litigation in the SMP Investigation and Litigation as follows:

Case No. A-24-886110-B:

The State commenced litigation by Complaint on January 30, 2024, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-24-886110-B. The State filed an Amended Complaint on November 21, 2024. This matter is stayed.

Case No. A-24-886113-B:

The State commenced litigation by Complaint on January 30, 2024, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-24-886113-B. This matter is stayed.

Case No. A-24-886115-B:

The State commenced litigation by Complaint on January 30, 2024, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-24-886115-B. The State filed an Amended Complaint on November 27, 2024. This matter is stayed.

Case No. A-24-886120-B:

The State commenced litigation by Complaint on January 30, 2024, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-24-886120-B. The State filed an Amended Complaint on November 27, 2024. This matter is stayed.

Case No. A-24-886127-B:

The State commenced litigation by Complaint on January 30, 2024, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-24-886127-B. The State filed an Amended Complaint on July 9, 2024, and a Second Amended Complaint on November 15, 2024. This matter is in discovery.

Case No. A-25-921270-B:

The State commenced litigation by Complaint on June 16, 2025, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-25-921270-B. The State filed an Amended Complaint on December 15, 2025. This matter is in motion practice.

Case No. A-25-925766-C:

The State commenced litigation by Complaint on August 15, 2025, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-25-925766-C. This matter is in motion practice.

3. Name of Each Party to the Matter

Case No. A-24-886110-B:

Plaintiff(s): STATE OF NEVADA

Defendant(s): META PLATFORMS, INC. f/k/a FACEBOOK, INC.

Case No. A-24-886113-B:

Plaintiff(s): STATE OF NEVADA

Defendant(s): SNAP, INC.

Case No. A-24-886115-B:

Plaintiff(s): STATE OF NEVADA

Defendant(s): META PLATFORMS, INC. f/k/a FACEBOOK, INC.

Case No. A-24-886120-B:

Plaintiff(s): STATE OF NEVADA

Defendant(s): META PLATFORMS, INC. f/k/a FACEBOOK, INC.; INSTAGRAM, LLC

Case No. A-24-886127-B:

Plaintiff(s): STATE OF NEVADA

Defendant(s): TIKTOK, INC.; BYTEDANCE INC.; BYTEDANCE LTD.; TIKTOK, LTD.; TIKTOK LLC

Case No. A-25-921270-B:

Plaintiff(s): STATE OF NEVADA

Defendant(s): GOOGLE LLC; YOUTUBE, LLC

Case No. A-25-925766-C:

Plaintiff(s): STATE OF NEVADA

Defendant(s): MEDIALAB AI, INC.; KIK

4. Amount of Recovery Obtained in the Matter

Case No. A-24-886110-B:

There were no recoveries obtained during the calendar year reporting period.

Case No. A-24-886113-B:

There were no recoveries obtained during the calendar year reporting period.

Case No. A-24-886115-B:

There were no recoveries obtained during the calendar year reporting period.

Case No. A-24-886120-B:

There were no recoveries obtained during the calendar year reporting period.

Case No. A-24-886127-B:

There were no recoveries obtained during the calendar year reporting period.

Case No. A-25-921270-B:

There were no recoveries obtained during the calendar year reporting period.

Case No. A-25-925766-C:

There were no recoveries obtained during the calendar year reporting period.

5. Amount of Costs and Expenses Paid in the Prosecution of the Matter for which No Recovery was Obtained

Case No. A-24-886110-B:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the calendar year reporting period.

Case No. A-24-886113-B:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the calendar year reporting period.

Case No. A-24-886115-B:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the calendar year reporting period.

Case No. A-24-886120-B:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the calendar year reporting period.

Case No. A-24-886127-B:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the calendar year reporting period.

Case No. A-25-921270-B:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the calendar year reporting period.

Case No. A-25-925766-C:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the calendar year reporting period.

6. Amount of Any Fee Paid pursuant to the Contract

A contingency fee has been negotiated that is dependent on the amount of recovery for the SMP Investigation and Litigation.

Case No. A-24-886110-B:

There were no amount of attorney fees paid during the calendar year reporting period.

Case No. A-24-886113-B:

There were no amount of attorney fees paid during the calendar year reporting period.

Case No. A-24-886115-B:

There were no amount of attorney fees paid during the calendar year reporting period.

Case No. A-24-886120-B:

There were no amount of attorney fees paid during the calendar year reporting period.

Case No. A-24-886127-B:

There were no amount of attorney fees paid during the calendar year reporting period.

Case No. A-25-921270-B:

There were no amount of attorney fees paid during the calendar year reporting period.

Case No. A-25-925766-C:

There were no amount of attorney fees paid during the calendar year reporting period.

III. Determinations and Exhibits

- There were no Determinations made in the calendar year reporting period.
- Exhibit A – Summary Totals
- Exhibit B – State Summary

IV. Contact

For additional information or questions, please contact Mark J. Krueger, Chief Deputy Attorney General, Office of the Nevada Attorney General, Bureau of Consumer Protection, at (775) 684-1298 or mkrueger@ag.nv.gov.

EXHIBIT A

Recovery and Allocation Summary Totals - Actual and Estimated (Revised 01-01-2026)
Opioid Settlement and Bankruptcy Actual and Estimated Annual Recoveries and Allocations Pursuant to the One Nevada Agreement
(assumes no default in payments)
(CMS Medicaid costs, if any, not deducted)
(assumes no administrative fees for court appointed third-party administrators)

<u>Settlement/Bankruptcy Name</u>	<u>Estimated/Actual Recovery Year</u>	<u>Estimated/Actual Recovery Month</u>	<u>Recoveries</u>	<u>Costs</u>	<u>Attorney Fees</u>	<u>Common Benefit Fund (CBF)</u>	<u>Net Allocation</u>
McKinsey (State)	2021	September	\$ 45,000,000.00	\$ 16,538,249.51	\$ 5,407,732.59	\$ -	\$ 23,054,017.90
Janssen - J&J	2022	April	\$ 50,833,353.00	\$ 8,397,545.43	\$ 7,037,053.92	\$ -	\$ 35,398,753.65
Distributors	2022	August	\$ 9,897,161.96	\$ -	\$ 1,641,228.64	\$ -	\$ 8,255,933.32
Distributors	2022	September	\$ 10,401,434.73	\$ -	\$ 1,724,851.29	\$ -	\$ 8,676,583.44
American Drug Stores	2022	November	\$ 1,500,000.00	\$ -	\$ 337,815.52	\$ -	\$ 1,162,184.48
Mallinckrodt (Bankruptcy)	2022	November	\$ 1,849,733.70	\$ -	\$ 416,579.22	\$ -	\$ 1,433,154.48
Mallinckrodt (Bankruptcy)	2022	November	\$ 40.00	\$ -	\$ -	\$ -	\$ 40.00
Distributors	2023	July	\$ 10,401,434.73	\$ -	\$ 1,724,851.29	\$ -	\$ 8,676,583.44
Allergan	2023	July	\$ 3,786,987.57	\$ -	\$ 383,282.32	\$ -	\$ 3,403,705.25
CVS (Costs)	2023	September	\$ 4,000,000.00	\$ 4,000,000.00	\$ -	\$ -	\$ -
CVS	2023	September	\$ 15,185,877.23	\$ -	\$ -	\$ 1,422,917.12	\$ 13,762,960.11
CVS (Fees)	2023	September	\$ 14,713,742.58	\$ -	\$ 14,713,742.58	\$ -	\$ -
Mallinckrodt (Fees Refund)	2023	October	\$ -	\$ -	\$ (416,579.22)	\$ -	\$ 416,579.22
Mallinckrodt (Bankruptcy)	2023	December	\$ 2,176,204.35	\$ -	\$ -	\$ -	\$ 2,176,204.35
Walgreens	2024	January	\$ 14,596,002.43	\$ -	\$ -	\$ 3,021,940.98	\$ 11,574,061.45
Teva (Costs)	2024	January	\$ 3,717,924.13	\$ 3,717,924.13	\$ -	\$ -	\$ -
Masters	2024	February	\$ 1,428,552.26	\$ -	\$ 331,123.22	\$ -	\$ 1,097,429.04
Walmart	2024	February	\$ 12,247,794.12	\$ -	\$ -	\$ -	\$ 12,247,794.12
Walmart	2024	March	\$ 19,016,311.93	\$ -	\$ -	\$ -	\$ 19,016,311.93
Distributors Prepayment	2024	April	\$ 5,730,223.57	\$ -	\$ 950,232.70	\$ -	\$ 4,779,990.87
Walmart (State Costs Fund)	2024	April	\$ 1,804,801.89	\$ 1,804,801.89	\$ -	\$ -	\$ -
Masters	2024	May	\$ 85,553.64	\$ -	\$ 19,830.45	\$ -	\$ 65,723.19
Allergan	2024	July	\$ 3,786,987.57	\$ -	\$ 383,282.32	\$ -	\$ 3,403,705.25
Allergan (Fees)	2024	July	\$ 3,287,105.21	\$ -	\$ 3,287,105.21	\$ -	\$ -
Teva	2024	July	\$ 7,000,000.00	\$ -	\$ -	\$ 2,014,627.32	\$ 4,985,372.68
Distributors	2024	August	\$ 13,018,868.99	\$ -	\$ 2,158,895.73	\$ -	\$ 10,859,973.26
CVS	2024	September	\$ 15,185,877.23	\$ -	\$ -	\$ 1,422,917.12	\$ 13,762,960.11
CVS (Fees)	2024	September	\$ 14,713,742.58	\$ -	\$ 14,713,742.58	\$ -	\$ -
McKinsey MDL (Local Govts)	2024	October	\$ 2,281,342.83	\$ -	\$ -	\$ -	\$ 2,281,342.83
Publicis	2024	November	\$ 4,122,056.40	\$ -	\$ 955,448.77	\$ -	\$ 3,166,607.63
Endo (Bankruptcy)	2024	November	\$ 3,808,546.82	\$ -	\$ -	\$ -	\$ 3,808,546.82
Walmart (Costs)	2024	November	\$ 1,510,167.63	\$ 1,510,167.63	\$ -	\$ -	\$ -
Walmart (Fee Funds)	2024	December	\$ 2,257,158.79	\$ -	\$ 2,257,158.79	\$ -	\$ -
Walgreens	2025	January	\$ 14,596,002.43	\$ -	\$ -	\$ 3,021,940.98	\$ 11,574,061.45
Walgreens (Fees)	2025	January	\$ 16,514,990.87	\$ -	\$ 16,514,990.87	\$ -	\$ -
Kroger	2025	May	\$ 2,428,923.84	\$ 391,062.57	\$ 472,354.55	\$ -	\$ 1,565,506.72

Kroger	2025	May	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Janssen - J&J	2025	June	\$ 2,675,439.63	\$ -	\$ 443,663.37	\$ -	\$ 2,231,776.26
Costs Adjustment (Refund)	2025	June	\$ -	\$ (60,392.04)	\$ -	\$ -	\$ 60,392.04
Allergan	2025	July	\$ 3,786,987.57	\$ -	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2025	July	\$ 7,000,000.00	\$ -	\$ -	\$ 2,014,627.32	\$ 4,985,372.68
Distributors	2025	August	\$ 13,018,868.99	\$ -	\$ 2,158,895.73	\$ -	\$ 10,859,973.26
CVS	2025	September	\$ 15,185,877.23	\$ -	\$ -	\$ 1,422,917.12	\$ 13,762,960.11
CVS (Fees)	2025	September	\$ 14,713,742.58	\$ -	\$ 14,713,742.58	\$ -	\$ -
Walmart	2025	November	\$ 241,732.78	\$ -	\$ -	\$ -	\$ 241,732.78
Walgreens	2026	January	\$ 14,596,002.43	\$ -	\$ -	\$ 3,021,940.98	\$ 11,574,061.45
Walgreens (Fees)	2026	January	\$ 16,514,990.87	\$ -	\$ 16,514,990.87	\$ -	\$ -
Apotex	2026	January	\$ 780,619.14	\$ -	\$ 180,939.23	\$ -	\$ 599,679.91
Alvogen	2026	January	\$ 228,981.61	\$ -	\$ 53,075.53	\$ -	\$ 175,906.08
Zydus	2026	January	\$ 182,144.47	\$ -	\$ 42,219.16	\$ -	\$ 139,925.31
Sun	2026	March	\$ 379,901.33	\$ -	\$ 88,057.11	\$ -	\$ 291,844.22
Mylan	2026	March	\$ 277,167.57	\$ -	\$ 64,244.49	\$ -	\$ 212,923.08
Mylan	2026	March	\$ 277,167.57	\$ -	\$ 64,244.49	\$ -	\$ 212,923.08
Amneal	2026	March	\$ 277,410.45	\$ -	\$ 64,300.82	\$ -	\$ 213,109.63
Amneal	2026	March	\$ 123,767.74	\$ -	\$ 28,688.08	\$ -	\$ 95,079.66
Hikma	2026	March	\$ 1,212,931.49	\$ -	\$ 281,144.66	\$ -	\$ 931,786.83
Indivior	2026	March	\$ 86,056.82	\$ -	\$ 19,947.08	\$ -	\$ 66,109.74
Indivior	2026	March	\$ 111,645.17	\$ -	\$ 25,878.22	\$ -	\$ 85,766.95
Kroger	2026	May	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Kroger (Additional Payment)	2026	May	\$ 53,802.64	\$ -	\$ 12,470.91	\$ -	\$ 41,331.73
Purdue-Sacklers	2026	June	\$ 8,691,272.26	\$ -	\$ 2,014,544.33	\$ -	\$ 6,676,727.93
Allergan	2026	July	\$ 3,786,987.57	\$ -	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2026	July	\$ 7,000,000.00	\$ -	\$ -	\$ 2,014,627.32	\$ 4,985,372.68
Distributors	2026	August	\$ 13,018,868.99	\$ -	\$ 2,158,895.73	\$ -	\$ 10,859,973.26
CVS	2026	September	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23
Walmart	2026	November	\$ 241,732.78	\$ -	\$ -	\$ -	\$ 241,732.78
Walgreens	2027	January	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Walgreens (Fees)	2027	January	\$ 16,514,990.87	\$ -	\$ 16,514,990.87	\$ -	\$ -
Mylan	2027	March	\$ 428,177.08	\$ -	\$ 99,246.93	\$ -	\$ 328,930.15
Amneal	2027	March	\$ 123,767.74	\$ -	\$ 28,688.08	\$ -	\$ 95,079.66
Indivior	2027	March	\$ 111,645.18	\$ -	\$ 25,878.22	\$ -	\$ 85,766.96
Kroger	2027	April	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Kroger (Additional Payment)	2027	April	\$ 107,605.29	\$ -	\$ 24,941.78	\$ -	\$ 82,663.51
Hikma	2027	May	\$ 86,056.82	\$ -	\$ 19,947.08	\$ -	\$ 66,109.74
Purdue-Sacklers	2027	June	\$ 5,794,181.51	\$ -	\$ 1,343,029.58	\$ -	\$ 4,451,151.93
Allergan	2027	July	\$ 3,786,987.57	\$ -	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2027	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2027	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
Distributors	2027	August	\$ 4,960,189.09	\$ -	\$ 822,539.29	\$ -	\$ 4,137,649.80
CVS	2027	September	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23
Walmart	2027	November	\$ 241,732.78	\$ -	\$ -	\$ -	\$ 241,732.78

Walgreens	2028	January	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Walgreens (Fees)	2028	January	\$ 16,514,990.88	\$ -	\$ 16,514,990.88	\$ -	\$ -
Mylan	2028	March	\$ 428,177.08	\$ -	\$ 99,246.93	\$ -	\$ 328,930.15
Amneal	2028	March	\$ 123,767.74	\$ -	\$ 28,688.08	\$ -	\$ 95,079.66
Indivior	2028	March	\$ 111,885.52	\$ -	\$ 25,933.92	\$ -	\$ 85,951.60
Kroger	2028	April	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Kroger (Additional Payment)	2028	April	\$ 25,064.89	\$ -	\$ 5,809.79	\$ -	\$ 19,255.10
Purdue-Sacklers	2028	June	\$ 5,794,181.51	\$ -	\$ 1,343,029.58	\$ -	\$ 4,451,151.93
Allergan	2028	July	\$ 3,786,987.57	\$ -	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2028	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2028	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
Distributors	2028	August	\$ 15,311,758.47	\$ -	\$ 2,539,121.46	\$ -	\$ 12,772,637.01
CVS	2028	September	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23
Walmart	2028	November	\$ 241,732.78	\$ -	\$ -	\$ -	\$ 241,732.78
Walgreens	2029	January	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Mylan	2029	March	\$ 428,177.10	\$ -	\$ 99,246.94	\$ -	\$ 328,930.16
Amneal	2029	March	\$ 123,767.74	\$ -	\$ 28,688.08	\$ -	\$ 95,079.66
Indivior	2029	March	\$ 420,618.00	\$ -	\$ 97,494.83	\$ -	\$ 323,123.17
Kroger	2029	April	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Purdue-Sacklers	2029	June	\$ 5,794,181.51	\$ -	\$ 1,343,029.58	\$ -	\$ 4,451,151.93
Allergan	2029	July	\$ 3,786,987.57	\$ -	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2029	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2029	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
Distributors	2029	August	\$ 15,311,758.47	\$ -	\$ 2,539,121.46	\$ -	\$ 12,772,637.01
CVS	2029	September	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2030	January	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Mylan	2030	March	\$ 428,177.10	\$ -	\$ 99,246.94	\$ -	\$ 328,930.16
Amneal	2030	March	\$ 123,767.74	\$ -	\$ 28,688.08	\$ -	\$ 95,079.66
Kroger	2030	April	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Purdue-Sacklers	2030	June	\$ 5,794,181.51	\$ -	\$ 1,343,029.58	\$ -	\$ 4,451,151.93
Teva	2030	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2030	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
Distributors	2030	August	\$ 15,311,758.47	\$ -	\$ 2,539,121.46	\$ -	\$ 12,772,637.01
CVS	2030	September	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2031	January	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Mylan	2031	March	\$ 428,177.10	\$ -	\$ 99,246.94	\$ -	\$ 328,930.16
Amneal	2031	March	\$ 159,122.83	\$ -	\$ 36,883.00	\$ -	\$ 122,239.83
Kroger	2031	April	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Purdue-Sacklers	2031	June	\$ 5,794,181.51	\$ -	\$ 1,343,029.58	\$ -	\$ 4,451,151.93
Teva	2031	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2031	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
Distributors	2031	August	\$ 12,871,078.28	\$ -	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
CVS	2031	September	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23

Walgreens	2032	January	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Mylan	2032	March	\$ 428,177.10	\$ -	\$ 99,246.94	\$ -	\$ 328,930.16
Amneal	2032	March	\$ 159,122.83	\$ -	\$ 36,883.00	\$ -	\$ 122,239.83
Kroger	2032	April	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Purdue-Sacklers	2032	June	\$ 5,794,181.50	\$ -	\$ 1,343,029.58	\$ -	\$ 4,451,151.92
Teva	2032	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2032	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
Distributors	2032	August	\$ 12,871,078.28	\$ -	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
CVS	3032	September	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2033	January	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Mylan	2033	March	\$ 499,470.17	\$ -	\$ 115,771.88	\$ -	\$ 383,698.29
Amneal	2033	March	\$ 159,122.83	\$ -	\$ 36,883.00	\$ -	\$ 122,239.83
Kroger	2033	April	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Purdue-Sacklers	2033	June	\$ 5,794,181.50	\$ -	\$ 1,343,029.58	\$ -	\$ 4,451,151.92
Teva	2033	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2033	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
Distributors	2033	August	\$ 12,871,078.28	\$ -	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Walgreens	2034	January	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Amneal	2034	March	\$ 159,122.84	\$ -	\$ 36,883.00	\$ -	\$ 122,239.84
Kroger	2034	April	\$ 2,428,923.79	\$ -	\$ 562,998.68	\$ -	\$ 1,865,925.11
Purdue-Sacklers	2034	June	\$ 5,794,181.50	\$ -	\$ 1,343,029.58	\$ -	\$ 4,451,151.92
Teva	2034	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2034	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
Distributors	2034	August	\$ 12,871,078.28	\$ -	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Walgreens	2035	January	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Purdue-Sacklers	2035	June	\$ 2,897,090.75	\$ -	\$ 671,514.81	\$ -	\$ 2,225,575.94
Teva	2035	July	\$ 7,000,000.00	\$ -	\$ -	\$ -	\$ 7,000,000.00
Distributors	2035	August	\$ 12,871,078.28	\$ -	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Walgreens	2036	January	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Teva	2036	July	\$ 7,000,000.00	\$ -	\$ -	\$ -	\$ 7,000,000.00
Distributors	2036	August	\$ 12,871,078.28	\$ -	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Walgreens	2037	January	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Teva	2037	July	\$ 9,000,000.00	\$ -	\$ -	\$ -	\$ 9,000,000.00
Distributors	2037	August	\$ 12,871,078.28	\$ -	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Walgreens	2038	January	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Teva	2038	July	\$ 9,000,000.00	\$ -	\$ -	\$ -	\$ 9,000,000.00
Distributors	2038	August	\$ 12,871,078.28	\$ -	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Teva	2039	July	\$ 9,000,000.00	\$ -	\$ -	\$ -	\$ 9,000,000.00
Teva	2040	July	\$ 9,000,000.00	\$ -	\$ -	\$ -	\$ 9,000,000.00
Teva	2041	July	\$ 9,000,000.00	\$ -	\$ -	\$ -	\$ 9,000,000.00
Teva	2042	July	\$ 27,000,000.00	\$ -	\$ -	\$ -	\$ 27,000,000.00
Teva	2043	July	\$ 27,000,000.00	\$ -	\$ -	\$ -	\$ 27,000,000.00

Subtotal Recoveries			\$ 1,185,143,427.09	\$ 36,299,359.12	\$ 236,665,322.85	\$ 19,378,456.26	\$ 892,800,288.86
Janssen - J&J (State Fee Fund)	2023	June	\$ 2,361,047.44	\$ -	\$ 2,361,047.44	\$ -	\$ 2,361,047.44
Janssen - J&J (State Fee Fund)	2023	June	\$ 2,242,797.39	\$ -	\$ 2,242,797.39	\$ -	\$ 2,242,797.39
Distributors (State Fee Fund)	2023	August	\$ 15,432,662.80	\$ -	\$ 15,432,662.80	\$ -	\$ 15,432,662.80
Janssen - J&J (State Fee Fund)	2023	September	\$ 64,306.55	\$ -	\$ 64,306.55	\$ -	\$ 64,306.55
Janssen - J&J (State Fee Fund)	2023	December	\$ 91.31	\$ -	\$ 91.31	\$ -	\$ 91.31
Distributors (State Fee Fund)	2023	December	\$ 735,956.63	\$ -	\$ 735,956.63	\$ -	\$ 735,956.63
Distributors (State Fee Fund)	2023	December	\$ 566,547.35	\$ -	\$ 566,547.35	\$ -	\$ 566,547.35
Distributors (State Fee Fund)	2023	December	\$ 589,362.17	\$ -	\$ 589,362.17	\$ -	\$ 589,362.17
Purdue (State Costs Share)	2024	January	\$ 2,230.14	\$ 2,230.14	\$ -	\$ -	\$ 2,230.14
Distributors (State Costs Fund)	2024	April	\$ 7,198,279.03	\$ 7,198,279.03	\$ -	\$ -	\$ 7,198,279.03
Janssen - J&J (State Costs Fund)	2024	April	\$ 1,160.73	\$ 1,160.73	\$ -	\$ -	\$ 1,160.73
Distributors (State Fee Fund)	2024	July	\$ 1,774.22	\$ -	\$ 1,774.22	\$ -	\$ 1,774.22
Janssen - J&J (State Fee Fund)	2024	August	\$ 302,274.45	\$ -	\$ 302,274.45	\$ -	\$ 302,274.45
Publicis (State Costs Fund)	2024	November	\$ 5,000.00	\$ 5,000.00	\$ -	\$ -	\$ 5,000.00
Endo (State Costs Fund)	2024	November	\$ 166,541.42	\$ 166,541.42	\$ -	\$ -	\$ 166,541.42
Mallinckrodt (State Fee Fund)	2025	April	\$ 156,859.83	\$ -	\$ 156,859.83	\$ -	\$ 156,859.83
MDL Order 42 (LG Fee Fund)	2025	May	\$ 30,863.18	\$ -	\$ 30,863.18	\$ -	\$ 30,863.18
Pharmacies (State Costs Fund)	2025	July	\$ 141,475.18	\$ 141,475.18	\$ -	\$ -	\$ 141,475.18
Purdue (State Costs Share)	2025	July	\$ 214,304.86	\$ 214,304.86	\$ -	\$ -	\$ 214,304.86
Subtotal Fee Fund and Costs Fund Recoveries			\$ 30,213,534.68	\$ 7,728,991.36	\$ 22,484,543.32	\$ -	\$ 30,213,534.68
			\$ 1,215,356,961.77	\$ 28,570,367.76	\$ 214,180,779.53	\$ 19,378,456.26	\$ 923,013,823.54
			Total Recoveries	Total Costs	Total Attorney Fees	Total CBF	Total Net Allocation

EXHIBIT B

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 01-01-2026)

State of Nevada - Actual and Estimated Allocations to the Fund for a Resilient Nevada

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement/Bankruptcy Name	Estimated/Actual Recovery Year	Estimated/Actual Recovery Month	Recoveries Allocation	Costs	Attorney Fees	Net Allocation
McKinsey (State)	2021	September	\$ 45,000,000.00	\$ 16,538,249.51	\$ 5,407,732.59	\$ 23,054,017.90
Janssen - J&J	2022	April	\$ 18,612,345.20	\$ -	\$ 3,536,345.59	\$ 15,075,999.61
Distributors	2022	August	\$ 4,340,895.22	\$ -	\$ 824,770.09	\$ 3,516,125.13
Distributors	2022	September	\$ 4,562,069.29	\$ -	\$ 866,793.17	\$ 3,695,276.12
American Drug Stores	2022	November	\$ 657,900.01	\$ -	\$ 131,580.00	\$ 526,320.01
Mallinckrodt (Bankruptcy)	2022	November	\$ 811,293.19	\$ -	\$ 162,258.64	\$ 649,034.55
Mallinckrodt (Bankruptcy)	2022	November	\$ 17.58	\$ -	\$ -	\$ 17.58
Distributors	2023	July	\$ 4,562,069.29	\$ -	\$ 866,793.17	\$ 3,695,276.12
Allergan	2023	July	\$ 1,660,972.77	\$ -	\$ 123,850.76	\$ 1,537,122.01
CVS	2023	September	\$ 6,877,247.99	\$ -	\$ -	\$ 6,877,247.99
CVS (Fees)	2023	September	\$ 5,731,040.01	\$ -	\$ 5,731,040.01	\$ -
Mallinckrodt (Fees Refund)	2023	October	\$ -	\$ -	\$ (162,258.64)	\$ 162,258.64
Mallinckrodt (Bankruptcy)	2023	December	\$ 954,483.23	\$ -	\$ -	\$ 954,483.23
Walgreens	2024	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Masters	2024	February	\$ 626,563.03	\$ -	\$ 134,711.05	\$ 491,851.98
Walmart	2024	February	\$ 5,371,882.50	\$ -	\$ -	\$ 5,371,882.50
Walmart	2024	March	\$ 8,340,554.42	\$ -	\$ -	\$ 8,340,554.42
Distributors Prepayment	2024	April	\$ 2,513,276.09	\$ -	\$ 477,522.46	\$ 2,035,753.63
Masters	2024	May	\$ 37,523.81	\$ -	\$ 8,067.62	\$ 29,456.19
Allergan	2024	July	\$ 1,660,972.77	\$ -	\$ 123,850.76	\$ 1,537,122.01
Allergan (Fees)	2024	July	\$ 1,458,406.49	\$ -	\$ 1,458,406.49	\$ -
Teva	2024	July	\$ 3,137,299.63	\$ -	\$ -	\$ 3,137,299.63
Distributors	2024	August	\$ 5,710,075.94	\$ -	\$ 1,084,914.43	\$ 4,625,161.51
CVS	2024	September	\$ 6,877,247.99	\$ -	\$ -	\$ 6,877,247.99
CVS (Fees)	2024	September	\$ 5,731,040.01	\$ -	\$ 5,731,040.01	\$ -
Publicis	2024	November	\$ 1,807,933.95	\$ -	\$ 388,705.80	\$ 1,419,228.15
Endo (Bankruptcy)	2024	November	\$ 1,670,428.65	\$ -	\$ -	\$ 1,670,428.65
Walmart (Fee Funds)	2024	December	\$ 989,989.85	\$ -	\$ 989,989.85	\$ -
Walgreens	2025	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Walgreens (Fees)	2025	January	\$ 6,718,803.74	\$ -	\$ 6,718,803.74	\$ -

Kroger	2025	May	\$ 893,805.93	\$ -	\$ 192,168.27	\$ 701,637.66
Kroger	2025	May	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Janssen - J&J	2025	June	\$ 1,173,447.82	\$ -	\$ 222,955.09	\$ 950,492.73
Costs Adjustment (Refund)	2025	June	\$ 26,487.95	\$ -	\$ -	\$ 26,487.95
Allergan	2025	July	\$ 1,660,972.77	\$ -	\$ 123,850.76	\$ 1,537,122.01
Teva	2025	July	\$ 3,137,299.63	\$ -	\$ -	\$ 3,137,299.63
Distributors	2025	August	\$ 5,710,075.94	\$ -	\$ 1,084,914.43	\$ 4,625,161.51
CVS	2025	September	\$ 6,877,247.99	\$ -	\$ -	\$ 6,877,247.99
CVS (Fees)	2025	September	\$ 5,731,040.01	\$ -	\$ 5,731,040.01	\$ -
Walmart	2025	November	\$ 106,024.00	\$ -	\$ -	\$ 106,024.00
Walgreens	2026	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Walgreens (Fees)	2026	January	\$ 6,718,803.74	\$ -	\$ 6,718,803.74	\$ -
Apotex	2026	January	\$ 342,379.56	\$ -	\$ 73,611.61	\$ 268,767.95
Alvogen	2026	January	\$ 100,431.33	\$ -	\$ 21,592.74	\$ 78,838.59
Zydus	2026	January	\$ 79,888.55	\$ -	\$ 17,176.04	\$ 62,712.51
Sun	2026	March	\$ 166,624.73	\$ -	\$ 35,824.32	\$ 130,800.41
Mylan	2026	March	\$ 121,565.67	\$ -	\$ 26,136.62	\$ 95,429.05
Mylan	2026	March	\$ 121,565.67	\$ -	\$ 26,136.62	\$ 95,429.05
Amneal	2026	March	\$ 121,672.23	\$ -	\$ 26,159.53	\$ 95,512.70
Amneal	2026	March	\$ 54,284.54	\$ -	\$ 11,671.18	\$ 42,613.36
Hikma	2026	March	\$ 531,991.75	\$ -	\$ 114,378.23	\$ 417,613.52
Indivior	2026	March	\$ 37,744.52	\$ -	\$ 8,115.07	\$ 29,629.45
Indivior	2026	March	\$ 48,967.56	\$ -	\$ 10,528.03	\$ 38,439.53
Kroger	2026	May	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Kroger (Additional Payment)	2026	May	\$ 23,597.83	\$ -	\$ 5,073.53	\$ 18,524.30
Purdue-Sacklers	2026	June	\$ 3,811,991.99	\$ -	\$ 819,578.28	\$ 2,992,413.71
Allergan	2026	July	\$ 1,660,972.77	\$ -	\$ 123,850.76	\$ 1,537,122.01
Teva	2026	July	\$ 3,137,299.63	\$ -	\$ -	\$ 3,137,299.63
Distributors	2026	August	\$ 5,710,075.94	\$ -	\$ 1,084,914.43	\$ 4,625,161.51
CVS	2026	September	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walmart	2026	November	\$ 106,024.00	\$ -	\$ -	\$ 106,024.00
Walgreens	2027	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Walgreens (Fees)	2027	January	\$ 6,718,803.74	\$ -	\$ 6,718,803.74	\$ -
Mylan	2027	March	\$ 187,798.44	\$ -	\$ 40,376.66	\$ 147,421.78
Amneal	2027	March	\$ 54,284.54	\$ -	\$ 11,671.18	\$ 42,613.36
Indivior	2027	March	\$ 48,967.57	\$ -	\$ 10,528.03	\$ 38,439.54
Kroger	2027	April	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Kroger (Additional Payment)	2027	April	\$ 47,195.68	\$ -	\$ 10,147.07	\$ 37,048.61
Hikma	2027	May	\$ 37,744.52	\$ -	\$ 8,115.07	\$ 29,629.45
Purdue-Sacklers	2027	June	\$ 2,541,328.00	\$ -	\$ 546,385.52	\$ 1,994,942.48

Allergan	2027	July	\$ 1,660,972.77	\$ -	\$ 123,850.76	\$ 1,537,122.01
Teva	2027	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2027	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
Distributors	2027	August	\$ 2,175,538.93	\$ -	\$ 413,352.40	\$ 1,762,186.53
CVS	2027	September	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walmart	2027	November	\$ 106,024.00	\$ -	\$ -	\$ 106,024.00
Walgreens	2028	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Walgreens (Fees)	2028	January	\$ 6,718,803.75	\$ -	\$ 6,718,803.75	\$ -
Mylan	2028	March	\$ 187,798.44	\$ -	\$ 40,376.66	\$ 147,421.78
Amneal	2028	March	\$ 54,284.54	\$ -	\$ 11,671.18	\$ 42,613.36
Indivior	2028	March	\$ 49,072.98	\$ -	\$ 10,550.69	\$ 38,522.29
Kroger	2028	April	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Kroger (Additional Payment)	2028	April	\$ 10,993.45	\$ -	\$ 2,363.59	\$ 8,629.86
Purdue-Sacklers	2028	June	\$ 2,541,328.00	\$ -	\$ 546,385.52	\$ 1,994,942.48
Allergan	2028	July	\$ 1,660,972.77	\$ -	\$ 123,850.76	\$ 1,537,122.01
Teva	2028	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2028	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
Distributors	2028	August	\$ 6,715,737.27	\$ -	\$ 1,275,990.08	\$ 5,439,747.19
CVS	2028	September	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walmart	2028	November	\$ 106,024.00	\$ -	\$ -	\$ 106,024.00
Walgreens	2029	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Mylan	2029	March	\$ 187,798.45	\$ -	\$ 40,376.67	\$ 147,421.78
Amneal	2029	March	\$ 54,284.54	\$ -	\$ 11,671.18	\$ 42,613.36
Indivior	2029	March	\$ 184,483.01	\$ -	\$ 39,663.85	\$ 144,819.16
Kroger	2029	April	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Purdue-Sacklers	2029	June	\$ 2,541,328.00	\$ -	\$ 546,385.52	\$ 1,994,942.48
Allergan	2029	July	\$ 1,660,972.77	\$ -	\$ 123,850.76	\$ 1,537,122.01
Teva	2029	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2029	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
Distributors	2029	August	\$ 6,715,737.27	\$ -	\$ 1,275,990.08	\$ 5,439,747.19
CVS	2029	September	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2030	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Mylan	2030	March	\$ 187,798.45	\$ -	\$ 40,376.67	\$ 147,421.78
Amneal	2030	March	\$ 54,284.54	\$ -	\$ 11,671.18	\$ 42,613.36
Kroger	2030	April	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Purdue-Sacklers	2030	June	\$ 2,541,328.00	\$ -	\$ 546,385.52	\$ 1,994,942.48
Teva	2030	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2030	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
Distributors	2030	August	\$ 6,715,737.27	\$ -	\$ 1,275,990.08	\$ 5,439,747.19

CVS	2030	September	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2031	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Mylan	2031	March	\$ 187,798.45	\$ -	\$ 40,376.67	\$ 147,421.78
Amneal	2031	March	\$ 69,791.29	\$ -	\$ 15,005.13	\$ 54,786.16
Kroger	2031	April	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Purdue-Sacklers	2031	June	\$ 2,541,328.00	\$ -	\$ 546,385.52	\$ 1,994,942.48
Teva	2031	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2031	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
Distributors	2031	August	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
CVS	2031	September	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2032	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Mylan	2032	March	\$ 187,798.45	\$ -	\$ 40,376.67	\$ 147,421.78
Amneal	2032	March	\$ 69,791.29	\$ -	\$ 15,005.13	\$ 54,786.16
Kroger	2032	April	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Purdue-Sacklers	2032	June	\$ 2,541,328.01	\$ -	\$ 546,385.52	\$ 1,994,942.49
Teva	2032	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2032	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
Distributors	2032	August	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
CVS	3032	September	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2033	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Mylan	2033	March	\$ 219,067.60	\$ -	\$ 47,099.53	\$ 171,968.07
Amneal	2033	March	\$ 69,791.29	\$ -	\$ 15,005.13	\$ 54,786.16
Kroger	2033	April	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Purdue-Sacklers	2033	June	\$ 2,541,328.01	\$ -	\$ 546,385.52	\$ 1,994,942.49
Teva	2033	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2033	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
Distributors	2033	August	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
Walgreens	2034	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Amneal	2034	March	\$ 69,791.30	\$ -	\$ 15,005.13	\$ 54,786.17
Kroger	2034	April	\$ 1,065,325.96	\$ -	\$ 229,045.08	\$ 836,280.88
Purdue-Sacklers	2034	June	\$ 2,541,328.01	\$ -	\$ 546,385.52	\$ 1,994,942.49
Teva	2034	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2034	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
Distributors	2034	August	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
Walgreens	2035	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Purdue-Sacklers	2035	June	\$ 1,270,664.02	\$ -	\$ 273,192.76	\$ 997,471.26
Teva	2035	July	\$ 3,137,299.64	\$ -	\$ -	\$ 3,137,299.64
Distributors	2035	August	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50

Walgreens	2036	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Teva	2036	July	\$ 3,137,299.64	\$ -	\$ -	\$ 3,137,299.64
Distributors	2036	August	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
Walgreens	2037	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Teva	2037	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Distributors	2037	August	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
Walgreens	2038	January	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Teva	2038	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Distributors	2038	August	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
Teva	2039	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Teva	2040	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Teva	2041	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Teva	2042	July	\$ 12,101,012.85	\$ -	\$ -	\$ 12,101,012.85
Teva	2043	July	\$ 12,101,012.85	\$ -	\$ -	\$ 12,101,012.85
Subtotals Recoveries			\$ 535,415,769.51	\$ 16,538,249.51	\$ 103,043,637.61	\$ 415,833,882.39
Janssen - J&J (State Fee Fund)	2023	June	\$ 2,361,047.44	\$ -	\$ 2,361,047.44	\$ 2,361,047.44
Janssen - J&J (State Fee Fund)	2023	June	\$ 2,242,797.39	\$ -	\$ 2,242,797.39	\$ 2,242,797.39
Distributors (State Fee Fund)	2023	August	\$ 15,432,662.80	\$ -	\$ 15,432,662.80	\$ 15,432,662.80
Janssen - J&J (State Fee Fund)	2023	September	\$ 64,306.55	\$ -	\$ 64,306.55	\$ 64,306.55
Janssen - J&J (State Fee Fund)	2023	December	\$ 91.31	\$ -	\$ 91.31	\$ 91.31
Distributors (State Fee Fund)	2023	December	\$ 735,956.63	\$ -	\$ 735,956.63	\$ 735,956.63
Distributors (State Fee Fund)	2023	December	\$ 566,547.35	\$ -	\$ 566,547.35	\$ 566,547.35
Distributors (State Fee Fund)	2023	December	\$ 589,362.17	\$ -	\$ 589,362.17	\$ 589,362.17
Purdue (State Costs Share)	2024	January	\$ 2,230.14	\$ 2,230.14	\$ -	\$ 2,230.14
Distributors (State Costs Fund)	2024	April	\$ 7,198,279.03	\$ 7,198,279.03	\$ -	\$ 7,198,279.03
Janssen - J&J (State Costs Fund)	2024	April	\$ 1,160.73	\$ 1,160.73	\$ -	\$ 1,160.73
Distributors (State Fee Fund)	2024	July	\$ 1,774.22	\$ -	\$ 1,774.22	\$ 1,774.22
Janssen - J&J (State Fee Fund)	2024	August	\$ 302,274.45	\$ -	\$ 302,274.45	\$ 302,274.45
Publicis (State Costs Fund)	2024	November	\$ 5,000.00	\$ 5,000.00	\$ -	\$ 5,000.00
Endo (State Costs Fund)	2024	November	\$ 166,541.42	\$ 166,541.42	\$ -	\$ 166,541.42
Mallinckrodt (State Fee Fund)	2025	April	\$ 156,859.83	\$ -	\$ 156,859.83	\$ 156,859.83
Pharmacies (State Costs Fund)	2025	July	\$ 141,475.18	\$ 141,475.18	\$ -	\$ 141,475.18
Purdue (State Costs Share)	2025	July	\$ 214,304.86	\$ 214,304.86	\$ -	\$ 214,304.86
Subtotals Funds			\$ 30,182,671.50	\$ 7,728,991.36	\$ 22,453,680.14	\$ 30,182,671.50
			\$ 565,598,441.01	\$ 8,809,258.15	\$ 80,589,957.47	\$ 446,016,553.89
			Total Recoveries	Total Costs	Total Attorney Fees	Total Net Allocation